Novacyt Shares Bounce 11% Following the Launch of an Oncological Test
Novacyt shares rise 11.32% to €0.58 at midday in a bullish Paris market (CAC 40 +0.88%, SBF 120 +0.86%). The stock recovers after a challenging week, as the company announces the launch of a new genetic test for oncology. Over three months, the performance remains positive at +45%.
Launch of Yourgene Insight DPYD Test Revitalizes Interest in the Stock
The company announced the launch of Yourgene Insight DPYD, a genetic test designed to identify cancer patients with dihydropyrimidine dehydrogenase deficiency before chemotherapy. Initially developed in 2019, the test has been enhanced to detect 19 genetic variants, including the 14 recommended by the updated guidelines of the Association for Molecular Pathology and the American College of Medical Genetics and Genomics. This announcement comes during a busy period for the group based in Le Vésinet. On May 7, Chief Scientific Officer Joanne Mason resigned after six years in the role. A few days earlier, on April 30, the group published annual accounts showing a 4% increase in revenue to £20M and a reduced EBITDA loss to £7.8M. During the preliminary results announcement for 2025 (on January 21, 2026), the company targeted revenues of £19.8M and an EBITDA of -£8.5M for the fiscal year, presenting itself as a debt-free group.
Day's Rebound Only Partially Mitigates Weekly Decline of 38.5%
The 6.53% rebound during the session only partially offsets the recent drop: over seven days, the stock is still down 35%. Over one year, the performance remains positive at +29%, and over three months at +45%. The stock is trading at €0.555, above its three moving averages: the MM20 (€0.46) is 20.65% below the current price, the MM50 (€0.42) is 32.14% below, and the MM200 (€0.44) is 26.14% below, indicating a solid underlying momentum despite last week's correction. The RSI at 53 is in a neutral zone, with no significant buying or selling pressure. The stock is in the upper part of the Bollinger Bands (at 65%), with the next resistance level identified at €0.90. As a reminder, at the end of March, three executives had bought a significant number of shares at less than €0.39.
